Go or no go? A delayed decision on Evrenzo
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
A Spac makes it happen for 4D Pharma
The boom in blank-cheque companies could offer small UK developers a new route to a US stock market listing.
Merck gets on the Treg train with Pandion buy
Merck & Co pays $1.9bn for an intriguing but early approach in autoimmune disease.
Comirnaty is the real deal in the real world
Data from Israel’s real-world experience with Pfizer/Biontech’s Covid-19 vaccine should silence any doubters.
A three way battle beckons in GM1 gangliosidosis
Early data could give clues about whether gene therapies from Sio, Passage Bio or Lysogene will come out on top in this rare inherited disease.
The reckoning begins for biotech-focused Spacs
The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.
New US nod widens the net for Entresto
Entresto can now be used in five million of six million US heart failure patients, but Novartis admits ramp-up in the new population will be slow.
Bluebird split looks premature
Today’s safety scare with Lentiglobin calls into question the logic behind Bluebird’s planned business separation.
